Monitor for commercialization updates, including coding, coverage, and reimbursement decisions, as well as potential inclusion in Alzheimer's treatment guidelines. The approval is a positive catalyst, but the lack of an immediate commercial launch timeline tempers near-term revenue impact.
Price Chart
Executive Summary
Lantheus received FDA approval for TAUKLARIFY (florquinitau F 18), a tau PET imaging agent for evaluating Alzheimer's disease in adults with cognitive impairment. This expands Lantheus's radiopharmaceutical portfolio into the large and growing Alzheimer's diagnostic market, though the company is still assessing the path to commercial availability.
Key Facts
- FDA approval of TAUKLARIFY for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer's disease
- Approval supported by two blinded read studies (Study 1: PPA 80-88%, NPA 98-99%; Study 2: PPA 68-82%, NPA 93-99%) with high inter-reader agreement (Fleiss' kappa 0.92 and 0.86)
- Safety evaluated in 1,734 subjects; most common adverse reactions were headache (0.7%), nausea (0.2%), injection site reactions (0.1%), dizziness (0.1%), and abdominal discomfort (0.1%)
- Lantheus intends to assess the appropriate path toward broader commercial availability; no immediate launch timeline provided
- Limitation of use: safety and effectiveness not established for evaluation of non-Alzheimer's disease tauopathies
Financial Impact
No revenue or market size estimates provided; approval opens potential new revenue stream in Alzheimer's tau imaging, a market with >7 million U.S. patients
Risk Factors
- Commercialization path and timing uncertain; Lantheus is still assessing strategy
- Competition from other tau PET tracers and amyloid PET imaging
- Reimbursement and adoption dependent on clinical guidelines and disease-modifying therapy uptake
- Limitation of use restricts label to Alzheimer's disease evaluation only
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345281 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 5d ago | 8-K | $100.10 $99.80 | ▼ −0.30% | ▲ +0.22% | $100.10 (−0.00%) |
Oct 2, 2026 24d ago | DEFA14A | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.10 (−0.09%) |
Oct 2, 2026 24d ago | 8-K | $100.19 $99.95 | ▼ −0.24% | ▼ −0.79% | $100.10 (−0.09%) |
Sep 16, 2026 5w ago | DEFA14A | $100.80 $100.55 | ▼ −0.25% | ▼ −0.38% | $100.10 (−0.70%) |
Aug 26, 2026 8w ago | PREM14A | $100.82 $100.47 | ▼ −0.35% | ▼ −1.00% | $100.10 (−0.72%) |
Aug 14, 2026 10w ago | Press Release | $100.95 $100.91 | ▼ −0.04% | ▲ +0.43% | $100.10 (−0.85%) |
Aug 6, 2026 11w ago | 8-K | $101.07 $100.95 | ▼ −0.12% | ▼ −0.73% | $100.10 (−0.96%) |
Aug 3, 2026 12w ago | 8-K / DEFA14A | $101.11 $101.50 | ▲ +0.39% | ▲ +0.59% | $100.10 (−1.00%) |
Aug 3, 2026 12w ago | DEFA14A / 8-K | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.10 (−1.08%) |
Aug 3, 2026 12w ago | Press Release | $101.19 $101.11 | ▼ −0.08% | ▼ −1.88% | $100.10 (−1.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers